De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Rhythm Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Rhythm Pharmaceuticals' is David Meeker, benoemd in Jul2020, heeft een ambtstermijn van 8.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.23M, bestaande uit 9.7% salaris en 90.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.29% van de aandelen van het bedrijf, ter waarde MX$ 156.50M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.7 jaar en 5.1 jaar.

Belangrijke informatie

David Meeker

Algemeen directeur

US$7.2m

Totale compensatie

Percentage CEO-salaris	9.7%
Dienstverband CEO	4yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	3.7yrs
Gemiddelde ambtstermijn bestuur	5.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is David Meeker's beloning veranderd ten opzichte van Rhythm Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	n/a	n/a	-US$274m
Dec 31 2023	US$7m	US$705k	-US$185m
Sep 30 2023	n/a	n/a	-US$186m
Jun 30 2023	n/a	n/a	-US$182m
Mar 31 2023	n/a	n/a	-US$181m
Dec 31 2022	US$3m	US$652k	-US$181m
Sep 30 2022	n/a	n/a	-US$181m
Jun 30 2022	n/a	n/a	-US$176m
Mar 31 2022	n/a	n/a	-US$166m
Dec 31 2021	US$6m	US$630k	-US$70m
Sep 30 2021	n/a	n/a	-US$62m
Jun 30 2021	n/a	n/a	-US$60m
Mar 31 2021	n/a	n/a	-US$56m
Dec 31 2020	US$15m	US$262k	-US$134m
Sep 30 2020	n/a	n/a	-US$132m
Jun 30 2020	n/a	n/a	-US$134m
Mar 31 2020	n/a	n/a	-US$146m
Dec 31 2019	US$287k	n/a	-US$141m
Sep 30 2019	n/a	n/a	-US$133m
Jun 30 2019	n/a	n/a	-US$115m
Mar 31 2019	n/a	n/a	-US$87m
Dec 31 2018	US$282k	n/a	-US$74m
Sep 30 2018	n/a	n/a	-US$59m
Jun 30 2018	n/a	n/a	-US$53m
Mar 31 2018	n/a	n/a	-US$47m
Dec 31 2017	US$268k	n/a	-US$38m

Compensatie versus markt: De totale vergoeding ($USD 7.23M ) David } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de MX markt ($USD 1.38M ).

Compensatie versus inkomsten: De vergoeding van David is gestegen terwijl het bedrijf verliesgevend is.

CEO

David Meeker (70 yo)

4yrs

Tenure

US$7,230,457

Compensatie

Dr. David P. Meeker, M.D., had been Independent Non-Executive Director of Pharvaris N.V. (formerly known as Pharvaris B.V.) since January 1, 2021 and serves as its Independent Non-Executive Chair. Dr. Meek...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
David Meeker	Chairman	4yrs	US$7.23m	0.29% $ 156.5m
Hunter Smith	CFO & Treasurer	7yrs	US$2.31m	0.16% $ 87.8m
Joseph Shulman	Chief Technical Officer	4yrs	US$1.74m	0.000050% $ 27.3k
Yann Mazabraud	Executive VP & Head of International	3.8yrs	US$1.74m	0.057% $ 31.3m
Jennifer Lee	Executive VP & Head of North America	3.7yrs	US$2.11m	0.011% $ 6.1m
Christopher German	Corporate Controller	1.3yrs	geen gegevens	0.0013% $ 710.5k
Alastair Garfield	Chief Scientific Officer	no data	geen gegevens	geen gegevens
David Connolly	Head of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens
Jim Flaherty	Senior VP & General Counsel	3.7yrs	geen gegevens	geen gegevens
Sarah Ryan	Vice President of Sales & Marketing	no data	geen gegevens	geen gegevens
Pamela Cramer	Chief Human Resources Officer	3yrs	geen gegevens	0.049% $ 26.9m
Elisabeth Cronert-Bendell	Senior VP & Head of Strategy	2.4yrs	geen gegevens	geen gegevens

3.7yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RYTM * wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
David Meeker	Chairman	8.7yrs	US$7.23m	0.29% $ 156.5m
Christopher German	Corporate Controller	1.3yrs	geen gegevens	0.0013% $ 710.5k
Jennifer Good	Independent Director	5.1yrs	US$283.77k	0.0049% $ 2.7m
David W. McGirr	Independent Director	8.7yrs	US$308.77k	0.0049% $ 2.7m
Edward Mathers	Lead Independent Director	11.3yrs	US$328.77k	0.014% $ 7.9m
Lynn Tetrault	Independent Director	3.6yrs	US$298.77k	0.0049% $ 2.7m
William Chin	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Elizabeth Stoner	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Michael Camilleri	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Lee Kaplan	Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
John Amatruda	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Stuart Arbuckle	Independent Director	5yrs	US$301.27k	0.0049% $ 2.7m

5.1yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RYTM * wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.1 jaar).

Rhythm Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

Rhythm Pharmaceuticals, Inc. Announces Executive Promotions

High number of new directors

Recent updates

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for Imcivree® (Setmelanotide) in Patients as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome

Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Forecast to breakeven in 2026

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rhythm Pharmaceuticals, Inc. Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

Rhythm Pharmaceuticals, Inc. Announces Approval of IMCIVREE®? Setmelanotide Solution for Weight Management in Adult and Pediatric Patients

First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.05 loss in 1Q 2022)

Full year 2022 earnings released: US$3.48 loss per share (vs US$1.40 loss in FY 2021)

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces ?Imcivree (Setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-Term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity At Obesityweek® and Plans to Initiate Phase 3 Trial in Early 2023

Rhythm Pharmaceuticals, Inc. Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands the Marketing Authorization for Imcivree(R) (Setmelanotide)

Second quarter 2022 earnings released: US$0.89 loss per share (vs US$0.70 loss in 2Q 2021)

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

NICE Recommends Rhythm’s IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency

Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. Announces That European Commission Authorized Variation for Imcivree (Setmelanotide) to Allow for Dosing in Patients with POMC or LEPR Deficiency with Renal Impairment

Rhythm Pharmaceuticals, Inc. Announces FDA Approval of IMCIVREE for Use in Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Presents Initial Data from Long-Term Extension Trial Evaluating Setmelanotide in Rare Genetic Diseases of Obesity at ENDO 2022

Rhythm Pharmaceuticals, Inc. Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome At the Pediatric Endocrine Society 2022 Virtual Annual Meeting

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity

Forecast to breakeven in 2024

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

Rhythm Pharmaceuticals, Inc. Announces Executive Promotions

Rhythm Pharmaceuticals, Inc. Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)

Rhythm Pharmaceuticals, Inc. Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Patients with Genetic Obesity Disorder

High number of new directors

Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain

Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl and Alström Syndromes

Rhythm Pharmaceuticals, Inc Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity

Rhythm Pharmaceuticals, Inc. Announces European Commission Authorization of IMCIVREE

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Growth Index

Forecast to breakeven in 2024

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd